Skip to main content

Preparation of Wogonin from Radix Scutellariae and its Inhibitory Effects on the Growth of HepG2 Cells

Buy Article:

$68.00 + tax (Refund Policy)

Context: Wogonin as one of the main bioactive components of Radix Scutellariae is promising for cancer therapy. However efficiency of preparation of wogonin is low.

Objective: The present study was aimed to develop an efficient method for preparative separation of high-purity wogonin from Radix Scutellariae and evaluate its inhibitory effects on HepG2 cell proliferation.

Materials and Methods: Radix Scutellariae was hydrolyzed in water (pH 5) for 12 h and then extracted with 95% ethanol. The extractum was separated with 30-60 mesh polyamide resin column. Fraction with wogonin was subjected to highspeed countercurrent chromatography (HSCCC). Human HepG2 cells were cultured in different concentrations of prepared wogonin in vitro. Cell proliferation was evaluated by MTT.

Results: 525 mg of wogonin was obtained from 50 g of raw Radix Scutellariae, with a purity of 98.7%. Wogonin (12.5, 25, 50, 100 and 200 μM) dose-dependently inhibited the growth of HepG2 cells.

Conclusion: An efficient method for preparing high-purity wogonin was established.

Keywords: Extraction; Radix Scutellariae; high-speed countercurrent chromatography; polyamide resin column; preparation; wogonin

Document Type: Research Article

Publication date: 01 May 2016

More about this publication?
  • Current Pharmaceutical Analysis publishes authoritative reviews, written by experts in the field on all the most recent advances in pharmaceutical and biomedical analysis. All aspects of the field are represented including drug analysis, analytical methodology and instrumentation. The journal is essential to all involved in pharmaceutical, biochemical and clinical analysis.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content